Introduction
============

Epstein-Barr virus (EBV) is one of the first described human cancer viruses. EBV is associated with \~ 1% of cancers worldwide, including Burkitt lymphoma, nasopharyngeal carcinoma (NPC), Hodgkin lymphomas, NK/T cell lymphomas, and a subset of gastric carcinomas [@B1], [@B2]. The EBV genome typically exists as an episome in infected cells. The most well-described EBV carcinogenic mechanisms are mediated through EBV viral protein effects or EBV infection. Expression of EBV proteins, EBNA-1, EBNA-2, EBNA-3A/3B/3C, LMP-1 and LMP-2, causes B cell and epithelial cell proliferation, increases viability of Burkitt lymphoma and NPC cells, and induces DNA damage and genomic instability [@B3]-[@B6], while EBV infection promotes chronic inflammation and reduces anti-tumor immune surveillance in the epithelium [@B4].

The first reports of the integration of the EBV genome into host genomes date back to the 1980s [@B7]-[@B10]. Subsequent studies confirmed the frequent integration of full-length EBV genomes as well as DNA fragments in EBV-positive lymphoma and epithelial carcinomas including NPC and gastric carcinoma [@B11]-[@B21]. These findings suggest that integrated and episomal EBV DNA coexist in tumor cells *in vivo* and *in vitro*. The significance of viral integrations as they may relate to host genome abnormalities and ultimately the development of cancer is not well understood [@B22]. Thus, it is important to determine whether EBV randomly integrates into human genomes or not [@B23]-[@B27]. The discoveries that integration sites occasionally co-localize with regions containing cancer associated genes *JAK2*, *PD-L1* and *PD-L2* in gastric carcinomas and *BACH2*,*REL* and*BCL-11A* in Burkitt lymphoma cells raise the possibility that EBV integration can promote carcinogenesis [@B20], [@B28], [@B29]. However, these studies are limited by a small sample size and the absence of a systematic investigation of the EBV integration landscape on a genome-wide scale. To provide systematic insight into EBV integration in associated malignancies, we performed EBV-targeted ultra-deep sequencing and conducted a comprehensive survey of EBV integration in a variety of human malignancies. This work provides the first unbiased, genome-wide analysis of EBV integrations, and reveals the involvement of novel inflammation-related genes in NPC.

Results
=======

To perform comprehensive profiling of EBV integration, we conducted EBV-targeted ultra-deep sequencing on 177 NPCs, 39 gastric carcinomas, 25 NK/T cell lymphomas, 11 Hodgkin lymphomas, one nasopharyngitis tissue and the EBV-positive NPC cell line C666-1. A total of 197 EBV integration breakpoints were identified from 33 tumors and the C666-1 cell line (**Table [1](#T1){ref-type="table"} and Figure [S1](#SM0){ref-type="supplementary-material"}**). The integration rates were higher in the gastric carcinomas (25.6%; 95% confidence interval (CI): 13.0 - 42.1%) than in the NPC tumors (9.6%; 95% CI: 5.7 - 14.9%). We observed slightly more EBV integration positive samples in late-stage NPC tumors (stage III-IV) and large-size gastric cancers (\> 5 cm; **Table [S1](#SM0){ref-type="supplementary-material"}**). The EBV integration counts in positive tumor samples varied widely among tumor types and individual cases. Twenty-seven of the 34 positive samples harbored 1-2 breakpoints. The remaining positive samples (*n* = 7) contained more than two with one gastric cancer harboring an especially large number (118) of integration breakpoints. At least 2 EBV integration breakpoints were consistent between matched primary and metastatic NPC tumors from the same patient (**Figure [S2](#SM0){ref-type="supplementary-material"}**).

The 197 breakpoints were distributed over all 23 human chromosomes (**Figure [1](#F1){ref-type="fig"}A**). EBV showed a strong tendency to integrate near common fragile sites in both NPC and gastric cancer samples (**Figure [1](#F1){ref-type="fig"}B**). Similarly, two of the six breakpoints identified in NK/T cell lymphoma samples were located at the same common fragile site (**Table [S2](#SM0){ref-type="supplementary-material"}**). EBV also tended to integrate into microsatellite repeats in gastric carcinomas, but avoided SINE repeats in NPC and gastric carcinomas (**Figure [1](#F1){ref-type="fig"}C**; For details, see **Figure [S3](#SM0){ref-type="supplementary-material"} and Table [S2](#SM0){ref-type="supplementary-material"}**). Common fragile regions and microsatellite repeats are vulnerable to DNA damage, which increases the chance for EBV DNA insertion into host genomes through microhomology-mediated DNA repair.

We also tested the relative position of EBV integrations to genes in the human genome. We found that 75 breakpoints (38.1%) were located within known UCSC-annotated genes (**Figure [S4](#SM0){ref-type="supplementary-material"}**). The integration sites were slightly skewed toward gene body and promoter regions (26 breakpoints; 13.2%; **Figure [S4](#SM0){ref-type="supplementary-material"}**). Unlike HBV and HPV integrations, no associations were found between EBV integration sites and CpG islands, the repetitive elements other than microsatellite repeats, or the binding sites of the genome architecture regulator CCCTC-binding factor (CTCF; **Figure [S5](#SM0){ref-type="supplementary-material"}**).

We detected EBV integration in the proximity of tumor suppressor genes: *KANK1* in one NK/T cell lymphoma, *RB1CC1* in one Hodgkin lymphoma, and *DLEC1* in one NPC tumor (**Table [S2](#SM0){ref-type="supplementary-material"}**). Integrations in gastric carcinoma samples were associated with tumor suppressor genes *SETD2*, *KISS1*, *FHIT*, *PTEN* and *TET2* (**Table [S2](#SM0){ref-type="supplementary-material"}**). The integration breakpoints associated with the histone methyltransferase, *SETD2*, were located in a region 22 kb upstream of the gene (**Figure [2](#F2){ref-type="fig"}A**). In one NK/T cell lymphoma, a breakpoint was found 27 kb downstream of the tumor suppressor gene *KANK1*. The other EBV integration breakpoint in the same sample was identified 204 kb downstream of *JAK2*. Amplification was also detected in this region (**Figure [2](#F2){ref-type="fig"}B**). Common fragile regions were often co-localized with tumor suppressor genes; for example, the common fragile site FRA3B lies within the tumor suppressor gene *FHIT*. A number of studies have shown that tumor suppressor genes and common fragile regions are frequent targets of viral DNA integration [@B30], [@B31]. The breakpoints associated with tumor suppressor genes in our study showed significantly higher coverage in the targeted sequencing, which indicates that they were more likely to be clonal in the tumorigenesis (*P* \< 0.0001, unpaired, two-sided *t*-test). Integration could alter the expression or function of tumor suppressor genes and provide host cells with a selective advantage during tumorigenesis.

We also identified EBV integrations located within the introns of *CDK15* in the primary (**Figures S2A-B**) and metastatic (**Figures [2](#F2){ref-type="fig"}C, S2C and D**) NPC tumors from a single patient, and *TNFAIP3* and *PARK2* in two additional NPC tumors from two other patients (**Figures [2](#F2){ref-type="fig"}D-E**). These breakpoints were all supported by a high number of sequencing reads, suggesting clonal expansion of cancer cells after EBV integration (Table [S2](#SM0){ref-type="supplementary-material"}). Notably, *TNFAIP3*, *CDK15* and *PARK2* are all inflammation-related genes involved in the regulation of TNF-alpha-induced apoptosis/NF-κB pathways [@B32]-[@B34], and dysregulation of these pathways contributes to the development of EBV-associated cancers, including NPC [@B35]. We performed the immunohistochemistry staining of *CDK15*, *TNFAIP3* and *PARK2* proteins using the integrated and non-integrated NPC samples. We found that the protein levels of *CDK15*, *TNFAIP3* and *PARK2* were lower in the samples harboring EBV integrations into the introns of the respective genes. (**Figures [3](#F3){ref-type="fig"}A-C**). Using qPCR of *NF-κB* targeted genes and a luciferase reporter gene assay, we found that *NF-κB* activity was up-regulated in NPC cells with *TNFAIP3* knockdown (**Figure [S6](#SM0){ref-type="supplementary-material"}A**), confirming its role as an inhibitor of *NF-κB* pathway. In contrast, NF-κB activity was down-regulated, and nuclear localization of *p65* after TNF-α treatment was diminished in NPC cells with *CDK15* knockdown (**Figure [S6](#SM0){ref-type="supplementary-material"}B**), indicating that *CDK15* is positively related to the activation of the *NF-κB* pathway.

To investigate the mechanisms of EBV integration, we surveyed the distribution of the 197 EBV integration breakpoints in the EBV genome. EBV breakpoints were spread over the entire viral genome with multiple hotspots (**Figure [4](#F4){ref-type="fig"}A**). Breakpoints were enriched in the proximity of *oriP* and terminal repeats, while no breakpoints were detected within the two long internal repeats (**Figure [4](#F4){ref-type="fig"}B**). The tendency for EBV breakpoints to localize around *oriP* and terminal repeats indicated that EBV integration was related to viral genome replication. We further analyzed the microhomology (MH) sequences in the regions flanking integration sites. We found frequent microhomologies between the human genome and the EBV genome near integration breakpoints (**Figure [S2](#SM0){ref-type="supplementary-material"} and Figure [S7](#SM0){ref-type="supplementary-material"}**). Insertions of 2-10 bp were also observed near the EBV integration breakpoints (**Figures S2 and Figure [S7](#SM0){ref-type="supplementary-material"}**). Two EBV integrations containing MH sequences were observed in matched primary and metastatic NPC tumors from a single patient (**Figure [S2](#SM0){ref-type="supplementary-material"}**).

Methods
=======

Ethics statement
----------------

This study was approved by the institutional ethics committees of the Sun Yat-sen University Cancer Center (Guangzhou, China), the First Affiliated Hospital of Guangxi Medical University (Nanning, China), the Affiliated Hospital of Qingdao University (Qingdao, China), and Rui Jin Hospital (Shanghai, China). Written informed consent was obtained from each study participant.

Sample collection and DNA extraction
------------------------------------

Frozen samples were collected for isolation of genomic DNAs from the following tissue types: NPC (*n* = 177; the Sun Yat-sen University Cancer Center and the First Affiliated Hospital of Guangxi Medical University); gastric carcinoma (*n* = 39; the Sun Yat-sen University Cancer Center and the Affiliated Hospital of Qingdao University); NK/T cell lymphoma (*n* = 25; the Sun Yat-sen University Cancer Center and Rui Jin Hospital); Hodgkin lymphoma (*n* = 11; the Sun Yat-sen University Cancer Center); and nasopharyngitis (*n* = 1; the Sun Yat-sen University Cancer Center). All histopathological diagnoses were performed according to WHO classifications and were reviewed by two pathologists. The clinicopathological characteristics of the study subjects are listed in**Table [S1](#SM0){ref-type="supplementary-material"}**.

Genomic DNAs were extracted from the frozen tissue samples using the DNeasy Blood and Tissue Kit (Qiagen; Germantown, MD, USA).

EBV DNA capture and sequencing
------------------------------

Genomic DNA was subjected to hybrid capture using an EBV-targeting single-stranded DNA probe developed by MyGenostics (Beijing, China). Sequencing libraries were constructed by shearing genomic DNA into 150-200 bp fragments, followed by DNA purification, end blunting and adaptor ligation according to the instructions provided by Illumina (San Diego, CA, USA). The library concentrations were evaluated with a Bioanalyzer 2100 (Agilent Technologies; Santa Clara, CA, USA). EBV DNA was captured from the genomic DNA following the MyGenostics GenCap Target Enrichment Protocol (GenCap Enrichment, MyGenostics). The libraries were hybridized with EBV probes at 65°C for 24 h and then washed to remove uncaptured DNA. The eluted DNA fragments were amplified through 18 PCR cycles to generate libraries for sequencing. The libraries were subsequently quantified and subjected to paired-end sequencing (2 × 100 or 150 bp) on an Illumina HiSeq 2000 sequencer according to the manufacturer\'s instructions (Illumina).

Integration detection, validation and annotation
------------------------------------------------

Quality assessment of the raw reads was conducted using TrimGalore to remove adaptor sequences and low-quality reads. High-quality reads were aligned to the human (NCBI build 37, hg19) and EBV genomes (NC_007605.1) using the Burrows-Wheeler Aligner (BWA, version 0.7.5a) [@B36]. Alignments were converted from a sequence alignment map format to sorted and indexed binary alignment map (BAM) files [@B37]. The Picard tool was used to remove duplicate reads. We developed a bioinformatic method based on LUMPY to identify EBV-human chimeric reads [@B38]. Briefly, paired-end reads mapping solely to the human or EBV reference genomes were removed. Next, two types of integration-supportive signals were extracted by LUMPY as follows: 1) read pairs, in which one of the paired reads was mapped to the EBV genome and the other to the human genome and 2) chimeric reads, in which one read covered both the EBV genome sequence and the human genome sequence. Integration events supported by ≥ 3 read pairs or chimeric reads were retained. ANNOVAR [@B39] and the UCSC table browser [@B40] were used to annotate the breakpoints using fragile regions [@B41], [@B42] and the UCSC hg19 CpG island and RepeatMasker database. We randomly selected 12 integrations and performed PCR and Sanger sequencing to validate. Ten (83.3%) breakpoints were validated with Sanger sequencing, while PCR for two breakpoints failed to generate products (**Table [S3](#SM0){ref-type="supplementary-material"}**).

Copy number variation and gene expression
-----------------------------------------

CNV data for three NK/T cell lymphomas were retrieved from the study by Jiang et al. [@B43]. Publicly available gene expression data for normal epithelium (*n* = 10) and NPC tumors (*n* = 31) obtained on the Affymetrix Human Genome U133 Plus 2.0 Array were retrieved from the NCBI GEO database (GSE12452). Probeset measures of all 41 arrays were calculated by robust multiarray averaging. The relative RNA expression value was log-transformed using log2. Data were analyzed with the unpaired t-test and presented as the mean ± SEM. A *P*-value of \< 0.05 was considered to be statistically significant.

siRNA transfection
------------------

*CDK15* and *TNFAIP3* siRNAs were designed and synthesized by RIBOBIO (Guangzhou, China). Non-targeting siRNA duplexes are denoted as "scr". Knockdown efficiency was confirmed with qPCR. Cells (7 × 10^5^) were seeded into 6 well plates, and after incubation overnight, transfected with the indicated siRNA duplexes using Lipofectiamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific; Waltham, MA, USA), according to the manufacturer\'s instructions. Sequences of the *CDK15* siRNAs were the following:

*CDK15*-siRNA\#1: 5\'-GAGGAAGGAGTCCCATTTA-3\'.

*CDK15*-siRNA\#2: 5\'-CCTCAGAACTTACTCATCA-3\'.

*TNFAIP3*-siRNA\#1: 5\'-GCGGAAAGCTGTGAAGATA-3\'.

*TNFAIP3*-siRNA\#2: 5\'-CAACTCACTGGAAGAAATA-3\'.

Quantitative Real-time PCR
--------------------------

Total RNA was isolated using Trizol reagent (Thermo Fisher Scientific), and cDNA was prepared from RNA (1 µg) using the PrimeScript RT Reagent Kit (TaKaRa; Tokyo, Japan) according to the manufacturer\'s instructions. Quantitative real-time PCR was performed using the Platinum SYBR Green qPCR SuperMix (Thermo Fisher Scientific) on a Light cycler 480 Real-time system (Roche; Indianapolis, IN, USA).

The primers sequences used were the following:

*CDK15*-F: 5\'-TATGCGACAGTTTACAAGG-3\'.

*CDK15*-R: 5\'-TCATGCAGGAGCACAATA-3\'.

*IKBα*-F: 5\'-CTCCGAGACTTTCGAGGAAATAC-3\'.

*IKBα*-R: 5\'-GCCATTGTAGTTGGTAGCCTTCA-3\'.

*IL6*-F: 5\'-ACTCACCTCTTCAGAACGAATT-3\'.

*IL6*-R: 5\'-CCATCTTTGGAAGGTTCAGGTTG-3\'.

*MCP1*-F: 5\'-CAGCCAGATGCAATCAATGC-3\'.

*MCP1*-R: 5\'-TGGAATCCTGAACCCACTTCT-3\'.

*TNF*-F: 5\'-CCTCTCTCTAATCAGCCCTCTG-3\'.

*TNF*-R: 5\'-GAGGACCTGGGAGTAGATGAG-3\'.

*GAPDH*-F: 5\'-TTGCCATCAATGACCCCTTCA-3\'.

*GAPDH*-R: 5\'-CGCCCCACTTGATTTTGGA-3\'.

Western blot analysis
---------------------

Western blot analysis was performed as previously described [@B44]. Cells were lysed in RIPA lysis buffer containing protease inhibitors (Roche). The subcellular fractionation was performed as previously described [@B45]. The proteins were separated with 10% SDS-PAGE and transferred to PVDF membranes (Thermo Fisher Scientific). Membranes were blocked with 5% BSA for 1 h and incubated with primary antibodies overnight in 4°C. Antibodies against *p65* (ab53465; Abcam; Cambridge, MA, USA), ß-actin (\#3700; Cell Signaling Technology; Danvers, MA, USA), and *GAPDH* (60004-1-1 g; Protein-tech; Chicago, IL, USA) were used for western blot analysis.

Luciferase reporter assay
-------------------------

(CAGA)12-Luc and the control vector pRL-TK (Promega) encoding Renilla luciferase were cotransfected into HEK293T or NPC cells using PEI. Luciferase activity was measured 24 h after transfection using the Dual-Luciferase Reporter Assay System (Promega). The firefly luciferase activity values were normalized to those of Renilla, and the ratios of firefly/Renilla activities were determined. The experiments were independently performed in triplicate.

Discussion
==========

EBV integration during tumorigenesis has not yet been systematically investigated using rigorous methods. In this study, we conducted the first large-scale analysis of EBV integration in multiple malignancies using EBV genome-targeted sequencing. Our method, combining EBV genome capture and ultra-deep sequencing, efficiently detected integrated EBV sequences from background "noise" introduced by nuclear EBV episomes. Our results indicate that EBV can integrate into host genomes at a significant rate in multiple tumor types. We observed that EBV integration frequencies varied among tumor types as well as the number of integrated EBV genomes among tumor samples. The heterogeneity of these tumor genomes may underlie the observed variation of EBV integration in these tumors.

Our study revealed that common fragile regions were preferred sites for EBV integration. Common fragile regions are genomic hotspots for DNA damage and are susceptible to genome rearrangement, thereby increasing the chance for EBV DNA insertion through microhomology-mediated DNA repair, which has an important role in the integration of other tumorigenic viruses, HBV and HPV [@B30], [@B31]. We observed EBV integrations into or near tumor suppressor genes that were often colocalized with common fragile regions. Integration in the proximity of tumor suppressor genes may provide host cells with a selective advantage. Moreover, integration distribution in gastric carcinomas correlated with microsatellite repeats which are vulnerable to DNA damage, one of the samples which has the 118 integration breakpoints, the whole-exome sequencing showed the mutation including *XRCC2*, *PARP3*, *SLX4*, and *PMS2*, which are involved in DNA repair, further suggesting that host genome stability has a strong impact on EBV integration. Although genome instability and microhomology-mediated DNA repair are involved in the integration of EBV, HPV and HBV DNA into the host genome, why does EBV integration occur at a relatively lower rate (25.6% in GC, 9.6% in NPC) than HPV integration in cervical cancer (76.3%) and head and neck squamous cell carcinoma (HNSCC; 60.7%), and HBV in hepatocellular carcinoma (HCC; 92.6%)? [@B31], [@B46]-[@B49]. There are several possible reasons. First, mechanisms underlying tumorigenesis and genetic backgrounds differ greatly between these tumor types associated with the different viruses. The tumor suppressors, *TP53* and *RB*, are inactivated by the expression of HPV-encoded oncogenes *E6* and *E7* in HPV-associated cervical cancer and HNSCC. Dysfunction of the *TP53* pathway has also been frequently observed in HBV-associated HCC (\~ 18-51.8%) [@B50]-[@B52]. The impairment of the TP53 pathway leads to increased genomic instability and accumulation of somatic mutations, possibly also contributing to the high rate of HPV and HBV integration. However, the *TP53* pathway is not mutated as frequently in NPC (\~ 7-10%) and EBV-associated gastric cancer (rarely) as in HCC [@B53]-[@B55]. Moreover, large-scale whole-genome surveys indicate that NPC and EBV-associated gastric carcinomas tend to have relatively stable genomes, compared to many other carcinomas including cervical cancer, HNSCC and HCC [@B53]. Second, life cycles and genomic features of the viruses themselves may also affect their integration into the host genome. In latent infection state, EBV episomes are replicated along with chromosomes in host cells and therefore are relatively stable. EBV has a much larger genome than HPV or HBV, which may make its integration by microhomology-mediated DNA recombination more difficult.

In NPC, three integration events were localized to introns of the inflammation-related genes *PARK2*, *TNFAIP3* and *CDK15*, which regulate the TNF-alpha-induced apoptosis/*NF-κB* pathways. *PARK2* deficiency promotes inflammation and genome instability and has an important role in the development of lung cancer [@B56]. Dysregulation of *NF-κB* activation contributes to the development of various EBV-associated cancers, including NPC [@B35]. We found lower expression of *PARK2*, *TNFAIP3* and *CDK15* proteins and also dysregulated *NF-κB* activity in the integrated NPC tumors. Our results suggest that integration of EBV into these genes may disrupt their function and contribute to tumorigenesis through the TNF-alpha-induced apoptosis/*NF-κB* pathways. The identification of integrations with a high number of supporting reads associated with inflammatory genes indicates that such EBV integration events are potentially selected for during tumor development. If these genes are involved in NPC development, they may be frequent targets of somatic mutation in NPC. *TNFAIP3* gene as a mutation hot spot has been already confirmed by previous studies in NPC [@B53]-[@B55]. We also searched our unpublished data and confirmed that about 5% of NPC tumors harbor copy number variation at *CDK15* and *PARK2* loci.

In the EBV genome, the breakpoints identified in this study were concentrated around *oriP* and the terminal repeats. During latency, EBNA1 binding to *oriP* can recruit host cell replication machinery to facilitate the formation of an efficient origin of replication for the EBV episome [@B57]. The terminal repeats are responsible for the circularization of the EBV genome after it enters the nucleus and cleavage/encapsulation of EBV DNA. Both EBV genome circularization and cleavage involve recombination events. The microhomology sequences around breakpoints indicate that EBV integration involves microhomology-mediated DNA repair pathways. These integrations may be triggered by genomic vulnerability/fragility during genome replication and the physical proximity of the *oriP* repeats to the host DNA bridged by EBNA1 and DNA recombination, which underlies the EBV integration mechanism.

Till now, we still do not know the size of the EBV sequence integrated into the host genome. Due to the limit of the read length in the second or third generation sequencing, we can only identify a few hundred base pair to around 10 Kb of EBV sequence fused into the host genome. Compared with the large size of the EBV genome, it is difficult to determine whether a portion or the full EBV genome is integrated into human genome. Future development of sequencing technology could help to map the landscape of EBV genome integrated into the human genome.

In summary, our work provides an unbiased large-scale genome-wide analysis of the EBV integration landscape in multiple malignancies. EBV integration occurs preferentially within unstable chromosomal regions of the host genome, surrounding *oriP* or terminal repeats of the EBV genome. Several integration sites were located in the proximity of tumor suppressor genes that are frequently disrupted during cancer progression. We detected multiple integrations into genes regulating TNF-alpha-induced apoptosis/*NF-κB* pathways in NPC. These pathways are closely related to EBV-associated diseases and indicate that EBV integration disrupts the function of crucial genes, leading to the development of cancer in some cases of latent EBV infection.
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![**Distribution of EBV integration breakpoints. (A)** Distribution of the 197 integration breakpoints across the human genome. For each integration breakpoint, each bar represents the total number of supporting reads at a specific locus in the human genome. Gene annotations for 23 breakpoints in 10 cancers and the C666.1 cell line supported by ≥ 9 EBV-DNA chimeric read pairs are labeled.**(B)** Distribution of 197 breakpoints in common fragile regions. The expected (assuming uniform and random distribution, blue) and observed ratios of EBV integration breakpoints detected in all samples (n=34, red, total), gastric carcinomas (n=10, green, GCT) and NPC (n=17, purple, NPCT) in common fragile regions are shown. *P*-values were calculated using the binomial exact test. **(C)** Significant enrichment of integration breakpoints with microsatellite repeats in gastric carcinomas. The expected and observed ratios of breakpoints co-localized with repeat elements LINE, SINE, LTR, DNA transposon and microsatellite in NPC (green, NPCT) and gastric carcinoma (red, GCT) are shown (for detailed frequencies, see Supplementary Figure. [3](#SM0){ref-type="supplementary-material"}). *P*-values were calculated using the binomial exact test. NS, non-significant; LINE, long interspersed nuclear element; SINE, long interspersed nuclear element; LTR, long terminal repeat.](thnov09p1115g001){#F1}

![**Mapping of EBV integration breakpoints in proximity of tumor suppressor and inflammation-related genes. (A-E)** The EBV integration breakpoints located in proximity of tumor suppressor genes: *SETD2* in one gastric carcinoma**(A)**, *KANK1* in one NK/T cell lymphoma**(B)**, and inflammation-related genes *CDK15* **(C)**, *TNFAIP3* **(D)** and *PARK2* **(E)** in NPC tumors. Red arrows indicate a transcription factor binding site near the EBV integration breakpoint. Three of the transcription factor binding sites are in the promoter, and one is in the EBV integration breakpoint.](thnov09p1115g002){#F2}

![**Gene expression in normal epithelium and NPC tumors. (A-C)** Immunohistochemical images of*CDK15***(A)**, *PARK2* **(B)**, *TNFAIP3* **(C)** expression in normal epithelium and NPC tumors with and without EBV integration. The red curve marks the neoplasm or epithelium, the rest is inflammatoryinfiltration. EBV (+) indicates positive for EBV integration; EBV (-) indicates negative for EBV integration.](thnov09p1115g003){#F3}

![**Distribution of integration breakpoints in the EBV genome. (A)** Distribution of breakpoints across the EBV genome. Histogram of the frequency of breakpoints was constructed for 1000 bp intervals. EBV genome annotation is shown. **(B)** Breakpoints enriched in *oriP* and terminal repeats in the EBV genome. The observed (blue) and expected (red) frequencies of breakpoints within fragments are shown. *P*-values were calculated using the binomial exact test.](thnov09p1115g004){#F4}

###### 

EBV integrations detected in EBV-associated malignancies

                       No. of integration positive samples (total samples)   Integration rate (95% confidence interval)   Total No. of breakpoints detected   No. of breakpoints per sample
  -------------------- ----------------------------------------------------- -------------------------------------------- ----------------------------------- -------------------------------
  Gastric carcinoma    10 (39)                                               25.6% (13.0 - 42.1%)                         153                                 0 - 118
  Hodgkin lymphoma     2 (11)                                                18.2% (2.3 - 51.8%)                          8                                   0 - 5
  NK/T cell lymphoma   4 (25)                                                16.0% (4.5 - 36.1%)                          6                                   0 - 2
  NPC                  17 (177)                                              9.6% (5.7 - 14.9%)                           28                                  0 - 6
  Nasopharyngitis      0 (1)                                                                                                                                  
  C666-1 cell line     1                                                                                                  2                                   
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